Market Cap 33.17M
Revenue (ttm) 0.00
Net Income (ttm) -24.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -5.31
Volume 556,500
Avg Vol 795,032
Day's Range N/A - N/A
Shares Out 48.05M
Stochastic %K 18%
Beta 3.24
Analysts Strong Sell
Price Target $7.00

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 903 8354
Address:
3 Dublin Landings, North Wall Quay, Dublin, Ireland
ThSealcubclubbingclub
ThSealcubclubbingclub Oct. 25 at 1:12 PM
0 · Reply
gandolf63
gandolf63 Oct. 25 at 1:05 PM
$ITRM Been one big pipe dream this past year. Ready to find the pot of gold
1 · Reply
gogo66so
gogo66so Oct. 25 at 1:00 PM
$ITRM Listed on Wellrx, Must still get from Alto 2,852.28 https://www.wellrx.com/prescriptions/orlynvah/
1 · Reply
gogo66so
gogo66so Oct. 25 at 12:19 PM
$ITRM ORLYNVAH™ Marks Major Advance in UTI Treatment Iterum Therapeutics plc announced the US commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets, following FDA approval in October 2024. The treatment is indicated for adult women with uncomplicated urinary tract infections (uUTIs) caused by E. coli, Klebsiella pneumoniae, or Proteus mirabilis who have limited or no alternative oral antibacterial options. As the first oral penem antibiotic available in the US and the first new branded therapy for uUTI in more than 25 years, ORLYNVAH™ addresses a growing need for effective treatments against multi-drug resistant infections. With resistance rates rising—57% of uUTIs resistant to at least one antibiotic class and 13% resistant to three or more—this launch offers a crucial new option for patients and clinicians. https://www.pm360online.com/healthcarewatch-15/
1 · Reply
gogo66so
gogo66so Oct. 25 at 12:16 PM
$ITRM Hospital Infection Therapeutics Market to Reach US$14.7 Billion by 2033. In October 2024, one new oral penem antibiotic, Orlynvah, was approved. Its primary indication is to target resistant strains of bacteria causing UTIs. These targeted therapies provide clinicians with much-needed new options to treat challenging hospital-acquired urinary tract infections, improving patient outcomes and addressing a critical area of AMR. https://www.globenewswire.com/news-release/2025/10/21/3170525/0/en/Hospital-Infection-Therapeutics-Market-to-Reach-US-14-7-Billion-by-2033-Astute-Analytica.html
1 · Reply
gogo66so
gogo66so Oct. 25 at 12:08 PM
$ITRM UTIs Might Be Coming From Your Grocery Cart https://gizmodo.com/utis-might-be-coming-from-your-grocery-cart-2000676662
0 · Reply
gogo66so
gogo66so Oct. 25 at 12:06 PM
$ITRM Looks like available more places than just Alto for $2934, Let her rip tater chip https://www.goodrx.com/orlynvah?srsltid=AfmBOop3YpBZQIqtoJ9R44oUDn7SHF_pEyFIUpjEakEWhd2m-RcHcVEZ
1 · Reply
MagaDaddy
MagaDaddy Oct. 25 at 11:36 AM
$ITRM Hey FishFuck, where are the PRs? and I’m not talking about prime rib.
1 · Reply
Alder77
Alder77 Oct. 25 at 8:32 AM
$ITRM Pfizer is currently thinking solely about Viking Therapeutics. They have a weight-loss drug that could generate revenues 1 million times higher than these. In fact, there's talk of a potential BO of 10 billion. If Pfizer hasn't purchased, it's because they're not interested in the tips. Our product, under full capacity, could generate revenues for 80 million years, which, when multiplied by the exclusivity period, gives it a potentially uninteresting value. I think another pharma will come forward, smaller, more modest, and more in line with our product. Pfizer sells non-therapeutic products, as per its credo, with high profitability. The problem of delays and long lead times is that our potential buyer is not like Pfizer, which has 30 billion in liquidity. This company is more modest and has limited liquidity, so it needs to be certain before spending.
0 · Reply
D1onysus
D1onysus Oct. 25 at 4:38 AM
$ITRM how iconic would it be if BO was 11/5/25
1 · Reply
Latest News on ITRM
Iterum Therapeutics to Present Data at IDWeek 2025

Oct 14, 2025, 8:30 AM EDT - 11 days ago

Iterum Therapeutics to Present Data at IDWeek 2025


Iterum Therapeutics Provides Business Update

Sep 19, 2025, 8:00 AM EDT - 5 weeks ago

Iterum Therapeutics Provides Business Update


Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:58 PM EDT - 2 months ago

Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript


Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript

May 13, 2025, 1:44 PM EDT - 5 months ago

Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript


Iterum Therapeutics Reports First Quarter 2025 Financial Results

May 13, 2025, 7:00 AM EDT - 5 months ago

Iterum Therapeutics Reports First Quarter 2025 Financial Results


Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript

Feb 7, 2025, 10:20 AM EST - 9 months ago

Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript


Iterum Therapeutics Regains Full Nasdaq Compliance

Nov 21, 2024, 8:30 AM EST - 1 year ago

Iterum Therapeutics Regains Full Nasdaq Compliance


US FDA approves Iterum's treatment for urinary infection

Oct 25, 2024, 10:57 AM EDT - 1 year ago

US FDA approves Iterum's treatment for urinary infection


Iterum Therapeutics to Present Data at IDWeek 2024

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Iterum Therapeutics to Present Data at IDWeek 2024


Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript

Aug 16, 2024, 11:27 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript


Iterum Therapeutics Commences Rights Offering

Jul 22, 2024, 7:30 AM EDT - 1 year ago

Iterum Therapeutics Commences Rights Offering


Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 10:08 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript


Iterum Therapeutics plc (ITRM) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 10:32 AM EST - 2 years ago

Iterum Therapeutics plc (ITRM) Q3 2023 Earnings Call Transcript


ThSealcubclubbingclub
ThSealcubclubbingclub Oct. 25 at 1:12 PM
0 · Reply
gandolf63
gandolf63 Oct. 25 at 1:05 PM
$ITRM Been one big pipe dream this past year. Ready to find the pot of gold
1 · Reply
gogo66so
gogo66so Oct. 25 at 1:00 PM
$ITRM Listed on Wellrx, Must still get from Alto 2,852.28 https://www.wellrx.com/prescriptions/orlynvah/
1 · Reply
gogo66so
gogo66so Oct. 25 at 12:19 PM
$ITRM ORLYNVAH™ Marks Major Advance in UTI Treatment Iterum Therapeutics plc announced the US commercial launch of ORLYNVAH™ (sulopenem etzadroxil and probenecid) oral tablets, following FDA approval in October 2024. The treatment is indicated for adult women with uncomplicated urinary tract infections (uUTIs) caused by E. coli, Klebsiella pneumoniae, or Proteus mirabilis who have limited or no alternative oral antibacterial options. As the first oral penem antibiotic available in the US and the first new branded therapy for uUTI in more than 25 years, ORLYNVAH™ addresses a growing need for effective treatments against multi-drug resistant infections. With resistance rates rising—57% of uUTIs resistant to at least one antibiotic class and 13% resistant to three or more—this launch offers a crucial new option for patients and clinicians. https://www.pm360online.com/healthcarewatch-15/
1 · Reply
gogo66so
gogo66so Oct. 25 at 12:16 PM
$ITRM Hospital Infection Therapeutics Market to Reach US$14.7 Billion by 2033. In October 2024, one new oral penem antibiotic, Orlynvah, was approved. Its primary indication is to target resistant strains of bacteria causing UTIs. These targeted therapies provide clinicians with much-needed new options to treat challenging hospital-acquired urinary tract infections, improving patient outcomes and addressing a critical area of AMR. https://www.globenewswire.com/news-release/2025/10/21/3170525/0/en/Hospital-Infection-Therapeutics-Market-to-Reach-US-14-7-Billion-by-2033-Astute-Analytica.html
1 · Reply
gogo66so
gogo66so Oct. 25 at 12:08 PM
$ITRM UTIs Might Be Coming From Your Grocery Cart https://gizmodo.com/utis-might-be-coming-from-your-grocery-cart-2000676662
0 · Reply
gogo66so
gogo66so Oct. 25 at 12:06 PM
$ITRM Looks like available more places than just Alto for $2934, Let her rip tater chip https://www.goodrx.com/orlynvah?srsltid=AfmBOop3YpBZQIqtoJ9R44oUDn7SHF_pEyFIUpjEakEWhd2m-RcHcVEZ
1 · Reply
MagaDaddy
MagaDaddy Oct. 25 at 11:36 AM
$ITRM Hey FishFuck, where are the PRs? and I’m not talking about prime rib.
1 · Reply
Alder77
Alder77 Oct. 25 at 8:32 AM
$ITRM Pfizer is currently thinking solely about Viking Therapeutics. They have a weight-loss drug that could generate revenues 1 million times higher than these. In fact, there's talk of a potential BO of 10 billion. If Pfizer hasn't purchased, it's because they're not interested in the tips. Our product, under full capacity, could generate revenues for 80 million years, which, when multiplied by the exclusivity period, gives it a potentially uninteresting value. I think another pharma will come forward, smaller, more modest, and more in line with our product. Pfizer sells non-therapeutic products, as per its credo, with high profitability. The problem of delays and long lead times is that our potential buyer is not like Pfizer, which has 30 billion in liquidity. This company is more modest and has limited liquidity, so it needs to be certain before spending.
0 · Reply
D1onysus
D1onysus Oct. 25 at 4:38 AM
$ITRM how iconic would it be if BO was 11/5/25
1 · Reply
thelonghull
thelonghull Oct. 25 at 2:54 AM
$ITRM https://www.reddit.com/r/science/comments/1oef7mf/nearly_1_in_5_urinary_tract_infections_linked_to/ interesting comment section, not directly related to Orlynvah, but ITRM has an addressable market for this drug
0 · Reply
1stPlace
1stPlace Oct. 25 at 2:53 AM
$ITRM Dotting the i(s) and crossing t(s). This is all done. Just waiting for news next week.
1 · Reply
stayskuntin11
stayskuntin11 Oct. 25 at 2:13 AM
$ITRM by February its either buyout or bust 🙏🏽 5 long years here ..i need a new car
0 · Reply
AppleJuice14
AppleJuice14 Oct. 25 at 1:16 AM
$ITRM man she just loves to finish in the $0.7 range. One day we’ll hit it big ladies and gentlemen (hopefully by EoY)
0 · Reply
Amb8675309
Amb8675309 Oct. 25 at 12:32 AM
$ITRM one other thought: if PFE really wanted Orlynvah, why didn’t they just buy it right after PDUFA? let’s say they lowballed, because they’re trying to get a deal. Then why give Corey 3 additional years to flounder around trying to commercialize? Perhaps they’re letting him jump into the deep end to see if he can swim, and if the launch is slow, they can then swoop in and get an even lower price in a few months? So this may all be a game of chicken. Crazy part is because of Alto pharmacy, PFE can see in real time how launch is going, so it really is biotech poker, but looks like the dealer can see all the cards. Will CF hold, fold or raise? Looks like that’s what the launch will show us
5 · Reply
FishinAround
FishinAround Oct. 25 at 12:12 AM
$ITRM You’d think that would be a great opportunity for a PR announcement. Like a story about their journey to get approval, a recap of what has happened since, and projections for a promising future and details for what they expect to accomplish and have already accomplished. Talk about the dent they are making and the good they are doing with some testimonies from patients and doctors. But no, not here, nothing to celebrate here!
0 · Reply
TROYTIPTON
TROYTIPTON Oct. 24 at 11:49 PM
$ITRM Another week in the books for the longs...and yet another repeated round of Irish long strokin's! No volume today...no interest from Big Pharma, institutions, retail...and damn sure...not from Corey and his insider posse who won't even come off of 70 bucks to buy of 100 shares of their own trash ..that's what they have y'all for! Enjoy the ride longs!! I'm sure they'll be riding you next week too!! 😅😂😊😭🤣😅
0 · Reply
Amb8675309
Amb8675309 Oct. 24 at 11:39 PM
$ITRM still here with big position. Not optimistic on “the buy out is coming THIS WEEK!” talk, but obviously a BO NOW would be great. Here’s what makes me think it’ll take longer: Post PDUFA, Fish received lowball offers- he’s mentioned that. He didn’t take them. Several months ago he negotiated with PFE to extend IOU out to 2029-why do that? He’s been clear that he intends to commercialize. These types of launches take MORE than a year. We have seen this in 17+ yrs in biotech-not asking GPT- just our experience. Fish is aware it’ll take time. Was told by analyst that we have a trifecta of things Wall Street doesn’t care about: women’s health, anti infectives and micro cap biotech- that’s why it’s been hard to get a BO offer that’s fair-one based on future peak sales, not 1st yr sales. Corey told me he’s always intended to commercialize in order to remove revenue risk and that’ll result in a BO # we and BOD will like. So the wait continues…
2 · Reply
Alder77
Alder77 Oct. 24 at 11:37 PM
$ITRM This man still has my respect. The only person who leaves comments on LinkedIn, on their official profile, on their latest post, the reality of things, and despite them being deleted, continues to post. Respect ✊
1 · Reply
MagaDaddy
MagaDaddy Oct. 24 at 11:29 PM
$ITRM No deal this week, but per FishFuck “The free Ice Cream and Donuts were unfucking believable”
1 · Reply
TROYTIPTON
TROYTIPTON Oct. 24 at 11:11 PM
$ITRM She may be hanging from the rafters in her attic. There was another joker who went by IamMBD who shared that he had over 400K of this trash. Folks likely need to send first responders to do welfare checks on these folks...they lost it all pretty much. So sad when people fall in love with a stock, especially this one....as there's nothing to live with ITRM.
1 · Reply
look2theblue
look2theblue Oct. 24 at 10:09 PM
$ITRM Let's assume she had 970,000 shares and was talking to the CEO periodically as she said, it's plausible she may have become aware of some material non-public information recently and is no longer allowed to speak. People with large activist positions do have access to information the rest of us don't.
2 · Reply